Clinical Studies – GSM2018-10-10T14:02:18+00:00

Gut Sensory Modulation (GSM) Clinical Testing Overview

Gut Sensory Modulation (GSM) has been tested in multiple, placebo-controlled, acute clinical studies between 2010 – 2013.  Results showed that various tastants (alone and in combination) could stimulate the release of L-cell hormones.  Ambra BioScience also demonstrated in a 16-week, placebo-controlled, study that these same tastants could produce statistically significant, categorical weight loss. 

Ambra conducted a 1-week, 220-subject, double-blind, placebo-controlled clinical study with the Lovidia® Hunger Control Formula in late 2015.  Reduced hunger was the endpoint and the results were statistically significant with a p-value = .02. 

In 2017, Ambra conducted a 13-week health outcomes study involving 52 healthy subjects using Lovidia in combination with intermittent fasting.  Subjects lost an average of 14 lbs. (7 % reduction in body weight) and significantly improved metabolic and cardiovascular indicators including reduced blood pressure, and improved lipids and glucose control.

In 2017, Ambra conducted a 7-day hunger control and weight loss study using the Lovidia Hunger Control Bar.  The Bar group lost an average of 4 lbs. compared to 0.5 lbs. without the bars.